Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors thank the patients and their families for their participation in this study.

Author contributions

Data analysis and interpretation were performed by CC, GV and PB. Collection and assembly of data were performed by CC and GI. Concept and design were undertaken by CC, GI, EC, AP, MJ, LS, MO, AF, MJC and SB. CC, GI, PA, DV, FB and PB contributed to manuscript writing. CC, GI, GV, EC, AP, MJ, LS, MO, AF, SB, PA, DV, MJC, FB AND PB contributed to final approval of the manuscript and are accountable for all aspects of the work (ensuring questions related to accuracy or integrity of the work are appropriately investigated and resolved).

Disclosure statement

C.C. has received honoraria and/or non-financial support from Regeneron, Novartis, and Takeda, not related with the present article. G.I. declares having received honoraria from Celgene, Gilead, Novartis, and Roche, not related with the present article. G.V. reported receiving honoraria for speaker activities from Merck Sharp & Dohme and advisory role from AstraZeneca. P.A. has received honoraria and/or non-financial support from Janssen, Roche, Celgene, Gilead, and AbbVie, not related with the present article. D.V. declares having received honoraria from Amgen, Novartis, Celgene, Pfizer, JAZZ, Astellas, and MSD, not related with the present article. F.B. declares having received honoraria and research grants from Roche, Celgene, Takeda, AstraZeneca, Novartis, AbbVie, and Janssen, not related with the present article. P.B. declares having received honoraria from Amgen, Celgene, Gilead, Incyte, Jazz Pharmaceuticals, MSD, Novartis, Pfizer, and Roche, not related with the present article. P.B. received funding from the Carlos III FIS16/01433 Health Institute, Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018–2020 grant from the Generalitat de Catalunya (BDNS357800).